NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-07

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

NCT06266832

Rectal Adenocarcinoma

RECRUITING PHASE2

A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer

NCT00122291

Rectal Cancer Neoplasm Metastasis

UNKNOWN PHASE2

Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer

NCT01129700

Rectal Cancer

COMPLETED PHASE2

Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer

NCT01340508

Rectal Cancers.

UNKNOWN PHASE2

Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer

NCT05622357

Locally Advanced Rectal Carcinoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced Rectal Cancer (LARC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NG-350A plus CRT during a 12-week active study treatment period

Group Type EXPERIMENTAL

NG-350A IV administration

Intervention Type DRUG

a tumour-selective anti-CD40-expressing adenoviral vector

Capecitabine oral administration

Intervention Type DRUG

chemotherapy

Radiotherapy

Intervention Type RADIATION

long-course intensity-modulated radiotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NG-350A IV administration

a tumour-selective anti-CD40-expressing adenoviral vector

Intervention Type DRUG

Capecitabine oral administration

chemotherapy

Intervention Type DRUG

Radiotherapy

long-course intensity-modulated radiotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed adenocarcinoma of the rectum.
* Locally advanced disease (clinical stage II-III based on pelvic MRI) selected by a multidisciplinary team for treatment with neoadjuvant CRT (which may be followed by CNCT to comprise planned TNT). Patients with oligometastatic disease are permitted provided that the site-specific multidisciplinary team deems them suitable for radical treatment/chemoradiation.
* Confirmed microsatellite stable (MSS)/proficient mismatch repair (pMMR) status.
* Provide written informed consent to participate.
* ECOG Performance Status 0 or 1.
* Must not be pregnant or breastfeeding.
* Patients who are sexually active (with either sex) must agree to comply with contraceptive requirements.
* Adequate lung reserve, renal function, hepatic function, and bone marrow/hematological function assessed ≤ 10 days prior to first dose.

Exclusion Criteria

* Recurrent rectal cancer.
* Distant metastatic disease not amenable to radical treatment/chemoradiation.
* Other prior malignancy active within the previous 3 years, except for local or organ confined early-stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease, and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the trial, including response rate and safety.
* Splenectomy (patients with prior partial resection remain eligible if the Investigator considers splenic function to not be significantly compromised).
* Active autoimmune disease that has required systemic therapy in the past 2 years, immunocompromised status in the opinion of the Investigator, or current treatment with systemic immunosuppressive therapy (daily prednisone equivalent for chronic system replacement not to exceed 10mg per day).
* Infectious or inflammatory bowel disease in the 3 months before the first dose of study treatment.
* Any clinically significant cardiovascular, peripheral vascular, cerebrovascular, or thromboembolic event in the last 1 month before the first dose of study treatment.
* Major surgery in the 14 days before the first dose of study treatment or any surgical wounds that are not fully healed and free of infection or dehiscence.
* Any prior surgery for rectal cancer or pelvic radiotherapy.
* Any other anti-cancer or experimental therapy within the previous 12 months or that is planned during the active study treatment period.
* Treatment with any other enadenotucirev-based virus (parent virus or transgene-modified variants), or anti-CD40 antibody at any time.
* History of prior Grade 3-4 acute kidney injury or other clinically significant renal impairment.
* Any ongoing Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 coagulation abnormality/coagulopathy.

URL:

https://www.FortressStudy.org

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No